Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Ehab El Bahesh"'
Publikováno v:
Case Reports in Hematology, Vol 2017 (2017)
Clinical Practice Points. Plasmablastic lymphoma (PBL) is a rare and highly aggressive variant of diffuse large B cell lymphoma with median survival of advanced stage patients varying between 6 and 15 months in previous reports. We report here a huma
Externí odkaz:
https://doaj.org/article/f0e783b529f74f2385f5ce05ebddfd85
Publikováno v:
Anticancer Research. 37:1547-1555
Acute graft versus host disease (aGVHD) remains the second leading cause of death following allogeneic hematopoietic stem cell transplant (AHSCT). Over the last five years, the progress in understanding the pathophysiology of this immune based-proces
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5b1fe1ddedbf1c714d514edd82a5b74b
https://doi.org/10.21873/anticanres.11483
https://doi.org/10.21873/anticanres.11483
Autor:
Marilyn Baird-Howell, Antoine Finianos, Paul H. Sugarbaker, Bruce Abell, Ehab El Bahesh, James D. Ahlgren
Publikováno v:
International Journal of Surgery Case Reports
Highlights • Meckel’s diverticulum is an outpouching of the distal small bowel. • This diverticulum may contain ectopic gastric epithelium which can become malignant. • A patient with gastric cancer with peritoneal metastases had the cancer o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::86f8d3db98ef8ce6873a7a4d5352a099
https://pubmed.ncbi.nlm.nih.gov/31399399
https://pubmed.ncbi.nlm.nih.gov/31399399
Publikováno v:
Anti-Cancer Agents in Medicinal Chemistry. 16:1166-1171
Prostate cancer is the most common cancer among American men and the second most common cause of cancer deaths among men. Treatment of prostate cancer remains a challenge. Despite decades of research, few cytotoxic chemotherapy agents have shown prom
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::477152e123d6fba1a25ece26a1241733
https://doi.org/10.2174/1871520616666160121113558
https://doi.org/10.2174/1871520616666160121113558
Publikováno v:
Future Oncology. 11:2395-2403
Management of metastatic castration-resistant prostate cancer has changed markedly over the last decade with major shifts in the treatment paradigm, although ultimately still will progress despite currently available therapies. The sequencing or comb
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::41f1b70b239348422ed93694c2f1fb7f
https://doi.org/10.2217/fon.15.168
https://doi.org/10.2217/fon.15.168
Publikováno v:
Case Reports in Hematology, Vol 2017 (2017)
Case Reports in Hematology
Case Reports in Hematology
Clinical Practice Points. Plasmablastic lymphoma (PBL) is a rare and highly aggressive variant of diffuse large B cell lymphoma with median survival of advanced stage patients varying between 6 and 15 months in previous reports. We report here a huma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::57eed6f8a9cb96236712f2817d2f843e
https://doaj.org/article/f0e783b529f74f2385f5ce05ebddfd85
https://doaj.org/article/f0e783b529f74f2385f5ce05ebddfd85
Publikováno v:
Anticancer research. 37(2)
Lung cancer is the leading cause of cancer-related death worldwide. Treatment of non-small cell lung cancer has evolved tremendously over the past decade. Specifically, immune checkpoint inhibitors have become an increasingly interesting target of ph
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3e4be5c6c921d1ecee16b0cd647668e5
https://pubmed.ncbi.nlm.nih.gov/28179283
https://pubmed.ncbi.nlm.nih.gov/28179283
Autor:
Joao L. Ascensao, Min-Ling Liu, Antoine Finianos, Fadi Alakeel, Dalia Mobarek, Ehab El-Bahesh, Hind Rafei
Publikováno v:
Blood. 128:3561-3561
Background: Novel molecular and immunophenotypic markers in Diffuse Large B-Cell Lymphoma (DLBCL) are of interest for potential therapeutic guidance in addition to prognostication. The cell-surface marker CD30 is expressed by several types of non-Hod
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::16a46ba7694516f5b0b3cbb5498e9e01
https://doi.org/10.1182/blood.v128.22.3561.3561
https://doi.org/10.1182/blood.v128.22.3561.3561
Autor:
Anita Aggarwal, Hind Rafei, Antoine Finianos, Joao L. Ascensao, Dalia Mobarek, Min-Ling Liu, Fadi Alakeel, Ehab El-Bahesh
Publikováno v:
Blood. 128:5396-5396
Background: MYC protein is expressed in 30-50% of diffuse large B cell lymphoma (DLBCL) and is associated with concomitant expression of BCL2 in 20% to 35% of cases. DLBCLs with co-expression of MYC and BCL2 are called double-expressor lymphomas (DEL
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0177cfc7d704376d6f930641a8e082f1
https://doi.org/10.1182/blood.v128.22.5396.5396
https://doi.org/10.1182/blood.v128.22.5396.5396
Autor:
Brandon Clark, Antoine Finianos, Kanika Gupta, Jeanny B. Aragon-Ching, Ehab El Bahesh, Samuel J. Simmens
Publikováno v:
Journal of Clinical Oncology. 34:414-414
414 Background: Bladder cancer is the sixth most common malignancy in the United States. Urothelial carcinoma makes up 90% of bladder cancer histology, which may be pure or mixed. It includes adenocarcinoma (Ad), squamous (SqC), glandular, sarcomatoi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bbf2fd7af72d79924897253de04598c7
https://doi.org/10.1200/jco.2016.34.2_suppl.414
https://doi.org/10.1200/jco.2016.34.2_suppl.414